Novartis Reports Results of Enerzair Breezhaler (QVM149) in P-IIIb ARGON Study to Treat Uncontrolled Asthma

Shots:

• The P-IIIb ARGON study involves assessing of IND/GLY/MF (150/50/80 μg , 150/50/160 μg, qd) with Sal/Flu (50/500μg, bid) delivered via Diskus + tiotropium (5 μg), delivered via Respimat in 1251 patients in a ratio (1:1:1) aged ≥18yrs. with uncontrolled asthma
• The study resulted in meeting its 1EPs demonstrating non-inferiority in change AQLQ. 2EPS include improvements in lung function, asthma control, health status, and a reduction in moderate exacerbations
• IND/GLY/MF has received CHMP’s positive opinion, based on IRIDIUM study and is currently under regulatory review in multiple countries including Switzerland and Japan. IND/GLY/MF will be available in the Breezhaler device which is hydrofluoroalkane/chlorofluorocarbon (HFA/CFC)-free

Click here to read full press release/ article | Ref: Novartis | Image: Twitter